Aquestive Therapeutics, Inc. reported on May 12, 2026, that it secured a five-year term loan facility of up to $150 million, utilizing $55 million immediately to repay existing debt and fund corporate needs. This financial move positions the company for future growth pending FDA approval for its drug Anaphylm.